Hif2alpha inhibitor rcc merck
WebBackground. Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a potent and selective small … Web28 de nov. de 2016 · A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors: Actual Study Start Date : December 7, 2016: Actual Primary Completion Date : January 12, 2024: Estimated Study Completion Date : April 14, 2025
Hif2alpha inhibitor rcc merck
Did you know?
Web29 de jul. de 2024 · The FDA has granted a breakthrough therapy designation to MK-6482 for the treatment of patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) with nonmetastatic renal cell carcinoma tumors less than 3 centimeters in size, unless immediate surgery is required, according to Merck (MSD), the company … WebIn the efficacy analysis set (N = 41), ORR was 22% (9 PRs) and DCR was 90%; 88% of pts had tumor shrinkage. Median DOR was not reached (range, 3.7+ to 14.8+ mo); all responses were ongoing as of the data cutoff date. Median PFS was 16.8 mo (95% CI, 9.2 to not reached); PFS rate at 12 mo was 65%; OS rate at 12 mo was 81%.
Web29 de jul. de 2024 · MK-6482 (formerly PT2977) is an investigational, novel, potent, selective, oral HIF-2α inhibitor that is currently being evaluated in a Phase 3 trial in advanced RCC (NCT04195750), a Phase 2 ... Web20 de jul. de 2024 · The pivotal phase 3 CONTACT-03 trial has been launched with the goal of exploring the combination of the multikinase inhibitor cabozantinib (Cabometyx) with the PD-L1 inhibitor atezolizumab (Tecentriq) in patients with advanced renal cell carcinoma (RCC) and prior exposure to an immune-checkpoint inhibitor. 1 CONTACT-03 is …
Web12 de mai. de 2024 · It is an oral, first-in-class, first-in-human HIF-2α inhibitor that targets the transcription factor HIF-2α. Clear cell RCC is defined by VHL alterations that lead to … Web29 de jul. de 2024 · FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Web5 de ago. de 2024 · Background In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resistance is common, therefore new …
WebBackground. Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a potent and selective small molecule HIF-2α inhibitor that prevents HIF-2α from heterodimerizing with HIF-1β, blocking the expression of HIF-2α target genes in tumour cells, and inducing regressions in … six the tourWeb16 de mar. de 2024 · Merck is also studying belzutifan in advanced RCC and other tumor types through a broad clinical program. In addition to the ongoing Phase 2 Study-004 … sushi on buffet fairfaxWeb13 de mai. de 2024 · Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau ... (VHL) Disease and Renal Cell … six the television pilotWeb15 de dez. de 2011 · Consequently, VHL-deficient RCC cell lines cannot degrade HIFα subunits in an O 2-dependent manner, and have been used extensively to investigate the roles of HIF1α and HIF2α in tumour growth. sushi on brookhurstWeb16 de mar. de 2024 · For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases ... sushi on burrardWeb29 de jul. de 2024 · Reinforces Important Progress in Merck’s Oncology Pipeline to Advance Novel Therapeutic Candidates Merck (NYSE: MRK), known as MSD outside the United … sushi on buffetWeb13 de ago. de 2024 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. … sushi on burnet